Research

Chronic Antiviral Therapy for Ocular Zoster (with or without the Zoster Eye Disease Study Data)

AAO JournalJust now1 min read

Infection with varicella zoster virus (VZV) causes the exanthem varicella, as well as establishing a life-long latent VZV infection of primary sensory neurons. Reactivation of this latent infection may cause classic dermatomal zoster, limited dermatomal zoster, disease without skin eruption, or even viral shedding in the absence of clinical disease, including viremia in otherwise healthy individuals. Recurrent zoster is not uncommon, with a 10-year cumulative risk of 9.9% for recurrent dermatomal zoster in patients who are immunocompetent and unvaccinated1 and a 6.3-year cumulative risk of 23% for recurrent VZV of the eye or globe after an initial episode of ophthalmic zoster with a classic rash in the V1 dermatome.

Read full article on AAO Journal

AI Summary

Quick Take

Varicella zoster virus (VZV) poses a significant long-term threat to ocular health, with nearly one-quarter of patients experiencing a recurrence within approximately six years of an initial ophthalmic episode. While the virus remains latent in sensory neurons, reactivation can manifest as classic dermatomal zoster or even occur without a skin eruption, complicating diagnosis and management.

Why It Matters

The high recurrence rate—23% over 6.3 years for ocular VZV—underscores the limitations of treating ophthalmic zoster as an isolated acute event. For clinicians, this data highlights the persistent nature of the virus and the potential necessity of chronic suppressive antiviral therapy to prevent vision-threatening relapses. Understanding that viral shedding and viremia can occur even in healthy individuals without clinical disease shifts the focus toward more proactive, long-term monitoring and potentially more aggressive preventative strategies for these patients.

Key Findings

The 6.3-year cumulative risk for recurrent VZV of the eye or globe is 23% following an initial episode of ophthalmic zoster with a classic V1 rash.
Immunocompetent and unvaccinated patients face a 9.9% cumulative risk of recurrent dermatomal zoster over a 10-year period.
VZV reactivation can occur as classic dermatomal zoster, limited disease, or even viral shedding and viremia in the absence of clinical symptoms or skin eruptions.
The virus establishes a life-long latent infection in primary sensory neurons following the initial varicella infection.

Practice Implications

Clinicians should maintain a high index of suspicion for VZV recurrence in patients with a history of ophthalmic zoster, even if the classic dermatomal rash is absent. Given that nearly 1 in 4 patients will experience a recurrence within six years, practitioners should consider discussing the risks of relapse and the potential role of chronic antiviral therapy with patients who have had V1 involvement.

Who's Affected

OphthalmologistsOptometristsCornea SpecialistsUveitis Specialists

Evidence StrengthModerate

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.